March 20, 2018
Pfizer’s leading brand Xtandi (enzalutamide) which earned the revenue of $590 million in 2017 has received Priority Review designation from the ...
Access articles & resources worth up to US $4, 000 per month.
Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.
Access articles & resources worth up to $4000.
First Oral Drug Reducing Risk of Blood Loss in Liver Disease Patients Gets Approved
Melinta Therapeutics Receives CARB-X Funding to Develop New Antibiotics Against Multiple “Superbugs”
First CAR-T GeneTherapy for Pediatric Blood Cancer ‘Kymriah’ Now Treats Adult Patients
First Drug to Treat Polycystic Kidney Disease Bags FDA Approval
7 New Ideas to Start a Healthcare Business in India (2018)
Pharma Patents: Can India Reward Incremental Innovation?